相关临床试验
675
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
607
89.9%
暂停
1
0.1%
终止
32
4.7%
Unknown
3
0.4%
撤回
32
4.7%
暂无批准数据
- HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, received final clearance from Florida's Agency for Health Care Administration to proceed with the acquisition of Dura Medical LLC, a revenue-generating and EBITDA-positive precision psychiatry clinic network. - Dura Medical provides comprehensive interventional psychiatry services including ketamine infusion therapy, transcranial magnetic stimulation, and Spravato® for treating severe depression, PTSD, and related CNS disorders in both veteran and civilian populations. - The acquisition, combined with previously announced purchases of Neurospa TMS and Cohen and Associates, will establish HOPE's coverage along Florida's west coast and support Dura's mission to treat more than 10,000 patients by 2026. - The deal represents a strategic expansion for HOPE's network of interventional psychiatry clinics, with Dura Medical founder Stephen Durand pioneering the combination of psychedelic medications with neuroplastic technologies for treating suicidal depression and PTSD.
• A large VA healthcare system study reveals that direct-acting antiviral (DAA) therapy significantly reduces hepatocellular carcinoma risk compared to no treatment in HCV patients with cirrhosis. • The research demonstrates comparable hepatocellular carcinoma risk reduction between DAA therapy and historical interferon treatments, with DAA achieving superior cure rates of over 95%. • Among study participants, 89.39% of DAA-treated patients achieved sustained virologic response, compared to 36.55% in the interferon-treated group, supporting DAA's favorable risk-benefit profile.
